Investments in Infrastructure

Investors bite the big pharma hands that feed them

Spending heavily on buybacks and dividends does not mean sector-leading share price performance, Evaluate Vantage finds.

Is a Pfizer break-up back on?

May 31, 2018

Stryker the surprise winner in the medtech spend versus sales stakes

May 30, 2018

On spend vs sales Pfizer is an outlier – but not always in a good way

April 26, 2018

Interview – Boehringer does digital health, San Francisco style

Boehringer gets diggi with it.

January 30, 2018

Amazon invites some friends to light a US healthcare bonfire

January 09, 2018

2017 saw the stars Align for big-cap medtech

Toothy grins all round at Align, but it is unclear how much longer it can keep up its scorching rate of sales growth.

November 13, 2017

Alnylam: The $12bn company with the $2bn war chest

October 17, 2017

How do you solve a problem like Maria?

October 05, 2016

Vantage point – What Brexit means for drug regulation

August 04, 2016

Big pharma’s R&D zero-to-hero story

Load More